25 June 2019 - Deborah Wilkes
Germany's Stada has appointed RB's Eelco Ockers as executive vice president for its home market with effect from 15 September 2019.
The managing directors of Stada's three German affiliates – Aliud Pharma, Stada and Stadapharm – will report directly to Ockers, who will be a member of Stada's global Executive Committee.
Ockers said he was "particularly committed to strengthening brands such as Grippostad and Ladival as well as developing the products and services of the generics affiliate Aliud Pharma and specialty pharmaceuticals supplier Stadapharm".
Stada's chief executive officer Peter Goldschmidt commented that Germany contributed "more than 30% to Stada's profits worldwide" and was the "core market of the group".
Goldschmidt added that Ockers was an "international brand professional who – together with the managing directors of the German affiliates – should make the generics and consumer health businesses as well as the specialty pharmaceutical segment even more successful".
Ockers, 43, has more than 15 years of experience at large companies including Procter & Gamble, RB and Unilever.
He joins Stada from RB where he is regional director for Germany, Austria and Switzerland (DACH) and the Nordic region. Stada said he was responsible for fast-moving consumer goods (FMCG), hygiene and home products.
Stada's financial performance
Worldwide sales at Germany's Stada were EUR2.33 billion (USD2.65 billion) in 2018, representing a rise as reported of 1% compared to 2017. Adjusted for portfolio and currency changes, sales were up by 5% (click here to read the News story).
The Branded Products business generated 40.7% of this figure, but worldwide sales were down by 0.4% to EUR948 million.
The remaining 59.3% was generated by the Generics business, which reported sales up by 2% to EUR1.36 billion.
Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE